Population Pharmacokinetic Analysis of Cilostazol in Healthy Subjects With Genetic Polymorphisms of CYP3A5, CYP2C19 andABCB1

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/j.1365-2125.2009.03558.x
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population

International Journal of Medical Sciences
Medicine
2015English

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects

Clinical Pharmacokinetics
Pharmacology
2009English

Influence of the CYP3A5 and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Tacrolimus in Healthy Korean Subjects

British Journal of Clinical Pharmacology
Pharmacology
2007English

Population Pharmacokinetic Modeling and Simulation of Fremanezumab in Healthy Subjects and Patients With Migraine

British Journal of Clinical Pharmacology
Pharmacology
2019English

Influence of CYP2C9 and CYP2C19 Genetic Polymorphisms on Pharmacokinetics of Gliclazide MR in Chinese Subjects

British Journal of Clinical Pharmacology
Pharmacology
2007English

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects

Drugs in R and D
Pharmacology
2011English

Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Depot Testosterone Cypionate in Healthy Male Subjects

English

Pharmacodynamic Interaction Studies of Ginkgo Biloba With Cilostazol and Clopidogrel in Healthy Human Subjects

British Journal of Clinical Pharmacology
Pharmacology
2007English

Genetic Polymorphisms in Warfarin and Tacrolimus-Related Genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot Population

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy